Skip to results
Modify your search
NARROW
1-20 of 86
Authors: Bruce E. Sands
Journal Article
Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies Open Access
Inflammatory Bowel Diseases, izaf038, https://doi.org/10.1093/ibd/izaf038
Published: 30 April 2025
Journal Article
Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program Open Access
Inflammatory Bowel Diseases, izaf036, https://doi.org/10.1093/ibd/izaf036
Published: 28 February 2025
Journal Article
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study Open Access
Inflammatory Bowel Diseases, izae253, https://doi.org/10.1093/ibd/izae253
Published: 25 October 2024
Journal Article
Mucosal and Transmural Healing and Long-term Outcomes in Crohn’s Disease Open Access
Inflammatory Bowel Diseases, Volume 31, Issue 3, March 2025, Pages 857–877, https://doi.org/10.1093/ibd/izae159
Published: 31 July 2024
Journal Article
EDITOR'S CHOICE
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study Open Access
Inflammatory Bowel Diseases, Volume 30, Issue 12, December 2024, Pages 2245–2258, https://doi.org/10.1093/ibd/izae024
Published: 09 March 2024
Journal Article
Dietary Interventions and Supplementation in Patients With an Ileal Pouch–Anal Anastomosis: A Systematic Review Free
Inflammatory Bowel Diseases, Volume 31, Issue 1, January 2025, Pages 246–258, https://doi.org/10.1093/ibd/izae037
Published: 07 March 2024
Journal Article
Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials Open Access
Inflammatory Bowel Diseases, Volume 30, Issue 12, December 2024, Pages 2335–2346, https://doi.org/10.1093/ibd/izae004
Published: 25 January 2024
Journal Article
An Insight into Patients’ Perspectives of Ulcerative Colitis Flares via Analysis of Online Public Forum Posts Open Access
Inflammatory Bowel Diseases, Volume 30, Issue 10, October 2024, Pages 1748–1758, https://doi.org/10.1093/ibd/izad247
Published: 02 November 2023
Journal Article
High Prevalence of Malnutrition and Micronutrient Deficiencies in Patients With Inflammatory Bowel Disease Early in Disease Course Free
Inflammatory Bowel Diseases, Volume 29, Issue 3, March 2023, Pages 423–429, https://doi.org/10.1093/ibd/izac102
Published: 19 May 2022
Journal Article
Current Trends in IBD—Development of Mucosal-Based Biomarkers and a Novel Minimally Invasive Recoverable Sampling System Free
Inflammatory Bowel Diseases, Volume 27, Issue Supplement_2, December 2021, Pages S17–S24, https://doi.org/10.1093/ibd/izab179
Published: 15 November 2021
Journal Article
Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program Open Access
Inflammatory Bowel Diseases, Volume 28, Issue 2, February 2022, Pages 234–245, https://doi.org/10.1093/ibd/izab056
Published: 20 March 2021
Journal Article
Longitudinal Autonomic Nervous System Measures Correlate With Stress and Ulcerative Colitis Disease Activity and Predict Flare Free
Inflammatory Bowel Diseases, Volume 27, Issue 10, October 2021, Pages 1576–1584, https://doi.org/10.1093/ibd/izaa323
Published: 31 December 2020
Journal Article
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies Open Access
Inflammatory Bowel Diseases, Volume 27, Issue 7, July 2021, Pages 994–1007, https://doi.org/10.1093/ibd/izaa236
Published: 23 September 2020
Journal Article
Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib—Implications for Cardiovascular Risk and Patient Management Open Access
Inflammatory Bowel Diseases, Volume 27, Issue 6, June 2021, Pages 797–808, https://doi.org/10.1093/ibd/izaa227
Published: 01 September 2020
Journal Article
Anastomotic Ulcers After Ileocolic Resection for Crohn’s Disease Are Common and Predict Recurrence Free
Inflammatory Bowel Diseases, Volume 26, Issue 7, July 2020, Pages 1050–1058, https://doi.org/10.1093/ibd/izz224
Published: 19 October 2019
Journal Article
Reply to Letter to the Editor of Dr. Lai and Colleagues Get access
Inflammatory Bowel Diseases, Volume 25, Issue 12, December 2019, Page e166, https://doi.org/10.1093/ibd/izz238
Published: 17 October 2019
Journal Article
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes Open Access
Inflammatory Bowel Diseases, Volume 25, Issue 11, November 2019, Pages 1854–1861, https://doi.org/10.1093/ibd/izz071
Published: 03 May 2019
Journal Article
Microbial Engraftment and Efficacy of Fecal Microbiota Transplant for Clostridium Difficile in Patients With and Without Inflammatory Bowel Disease Free
Inflammatory Bowel Diseases, Volume 25, Issue 6, June 2019, Pages 969–979, https://doi.org/10.1093/ibd/izy398
Published: 10 March 2019
Journal Article
P034 EFFICACY OF USTEKINUMAB IN CROHN’S DISEASE AT MAINTENENCE WEEK 56: IM-UNITI STUDY Get access
Inflammatory Bowel Diseases, Volume 25, Issue Supplement_1, February 2019, Pages S16–S17, https://doi.org/10.1093/ibd/izy393.039
Published: 07 February 2019
Journal Article
Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn’s Disease: A Post Hoc Analysis of GEMINI 2 and 3 Open Access
Inflammatory Bowel Diseases, Volume 25, Issue 8, August 2019, Pages 1375–1382, https://doi.org/10.1093/ibd/izy384
Published: 04 January 2019
